insiderwall
Menu
SuperinvestorInsider
Arbutus Biopharma Corporation ABUS

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep expertise in virology to create innovative treatments that target HBV

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees44
TickerABUS

Statistics

Market Cap$872.5M
Revenue (TTM)$14.1M
Net Income-$33.5M
Net Margin-237.9%
EPS$-0.17
P/E5.13
P/S4.40
P/B3.22
EV/EBITDA4.84
ROE94.7%
Dividend Yield
Price$4.43

Data: Twelve Data · Revenue = mcap / P/S